NAD+ Side Effects: The 'NAD Rush' Is a Speed Problem, Not a Toxicity Problem (2026)

Most NAD+ side effects are a speed problem, not a toxicity problem: the flushing, nausea, chest tightness, and cramping people feel during an IV drip or injection are almost entirely tied to how fast the NAD+ goes in, and they ease when you slow the drip or the push. This page answers the real tolerability question two ways at once: what 700 ProtocolPlus users report from real use, held honestly against the single most useful fact about NAD+ side effects, which is that the rate, not the molecule, is usually what makes you feel rough.

Most "NAD+ side effects" pages give you a generic list of mild effects and move on. We do it differently, because the list misses the pattern. The headline below is first-party community data from 700 ProtocolPlus users who tracked NAD+ tolerability, and the thing that ties almost all of it together is infusion rate. This is the phenomenon the community calls the "NAD rush": push NAD+ too fast and you get a wave of warmth, queasiness, and a tight feeling in the chest; slow it down and most of that wave recedes. One quick correction before the data, because it is why many readers land here: NAD+ is a coenzyme (a dinucleotide), not a peptide — it gets filed under "peptides" on clinic menus, but it has no amino-acid chain. For the molecule itself (what it is, how it works, IV versus oral precursors), this page links up to the NAD+ complete guide so it stays a clean safety-and-tolerability hub, and it sits within our roundup of the best peptides for longevity.

Key Takeaways

• The "NAD rush" (what our users report, N=700): the most-reported effects are flushing or warmth (30%, 210 users), nausea (24%, 168), and chest tightness or pressure (22%, 154), then an infusion-site reaction (16%), headache (14%), lightheadedness (12%), and cramping (12%). In our dataset every reported effect was mild or moderate — zero were severe.
• It is a RATE problem, not a toxicity problem. Almost all of these are tied to how fast the NAD+ is infused or injected. They peak when the drip is pushed too quickly and fade when you slow the drip or the push — which is why the single most effective fix is "slow down," not "stop NAD+."
• Slow the drip first. Clinic and community practice is to run NAD+ slowly (often over 2 to 4 hours for a full IV) and to pause or slow the rate the moment the rush starts. A small published infusion study that ran NAD+ at a slow ~2 mg/min over 6 hours reported no adverse events at all.
• Chest tightness is usually the rush — but take it seriously if you have cardiac history. For most people the tight-chest sensation is the hallmark rate-driven feeling and is benign; it resolves on slowing or finishing the infusion. If you have heart disease or any cardiac history, do not assume that — treat chest symptoms as a reason to stop and get checked.
• NAD+ is a coenzyme, not a peptide, and IV/injection NAD+ has no validated human side-effect incidence. Our figures are a self-reported community signal, not proof of safety and not validated rates.

What are the most common NAD+ side effects?

Across 700 ProtocolPlus users who tracked NAD+ tolerability, the most-reported effects are flushing or warmth (30%), nausea (24%), and chest tightness or pressure (22%) — and the unifying thread is that almost all of them are driven by how fast the NAD+ is infused, not by a toxic effect of the molecule. This is a community-report ranking from our own app data, not a validated incidence table, because no validated incidence table exists for IV or injected NAD+.

The list reads like the textbook description of the "NAD rush." After the top three, reports tail off into an infusion or injection-site reaction (16%, 112 users), headache (14%, 98), lightheadedness (12%, 84), abdominal cramping (12%, 84), increased heart rate (10%, 70), and then sweating, anxiety or restlessness, and fatigue (8% each, 56 users). In our dataset, eight of the eleven reported effects were tagged mild and three moderate; none were severe. The three "moderate" tags are nausea, chest tightness, and increased heart rate, which are exactly the effects people find most alarming in the moment and which respond most clearly to slowing the rate.

Read that list with the mechanism in mind, because it changes how you handle it. These shares come only from our community-reported dataset and describe what people experience and log, not trial-grade incidence and not causation. But the clustering is the point: flushing, nausea, chest tightness, and cramping are the classic fast-infusion sensations, and the community consensus, echoed by the clinics that administer NAD+, is that they ease when the drip slows. The mechanism behind each effect is below; for the molecule itself see the NAD+ complete guide.

Citation capsule. Among 700 ProtocolPlus users who tracked NAD+ tolerability, the most-reported effects were flushing/warmth (30%, 210 users), nausea (24%, 168), and chest tightness/pressure (22%, 154), followed by infusion-site reaction (16%), headache (14%), lightheadedness (12%), and cramping (12%); every reported effect was mild or moderate, none severe. This is first-party data reflecting what the community reports — self-reported, not validated trial incidence, and not proof of causation. IV/injection NAD+ has no validated human side-effect incidence. Source: ProtocolPlus app data (side-effects/nad-plus.json), 2026.

When is NAD+ chest tightness fine, and when should you stop the infusion?

For most people, the chest tightness or pressure during an NAD+ infusion is the hallmark of the rate-driven "NAD rush" — it appears when the drip runs too fast, it is usually benign, and it eases the moment you slow or pause the infusion. But if you have a heart condition or any cardiac history, do not assume that: treat chest symptoms as a reason to stop and get checked. This is the one effect on this page that deserves a clear decision rule, because the sensation is genuinely alarming even when it is harmless, and because "usually benign" is not the same as "always benign."

The reason the tight-chest feeling is so common with fast NAD+ is mechanistic, not a sign of cardiac damage: a rapid load of NAD+ drives transient vasodilation and smooth-muscle effects, and the body reads the wave as pressure or tightness in the chest or throat. In a published real-world pilot, every IV NAD+ recipient reported infusion-time symptoms including chest pressure that ceased immediately when the infusion finished, which is the signature of a rate effect rather than an injury. The practical rule clinics use is simple: at the first sign of the rush, slow or pause the drip, and the feeling usually settles within a minute or two. That is the difference between the benign rush and a true warning sign.

Citation capsule. In a 2026 real-world tolerability pilot, intravenous NAD+ recipients reported infusion-time symptoms including cramping, nausea, increased heart rate, throat pain, and chest pressure that ceased immediately on completion of the infusion, consistent with an infusion-rate effect rather than toxicity; a 2019 pilot that infused NAD+ slowly (about 2 mg/min over 6 hours) reported no adverse events. There is no validated incidence for IV/injection NAD+. Source: Reyna et al., Frontiers in Aging, 2026; Grant et al., Frontiers in Aging Neuroscience, 2019.

What does each NAD+ side effect feel like, and how does slowing the rate fix it?

Almost every common NAD+ effect is a fast-infusion sensation — flushing, nausea, chest tightness, cramping, a racing pulse — and the single lever that controls all of them is the rate: run the drip slowly and most of the rush never starts. Below is each reported effect, what it feels like, why the rate drives it, and how the community and clinics handle it. These are descriptions of common practice, not a prescription — dose and rate decisions belong with the clinician giving the infusion, and for how protocols are structured the NAD+ dosage calculator lays out the reported ranges.

Flushing and warmth (30%, 210 users)

The single most-reported effect, and the most benign: a spreading warmth or flush, often in the face and chest, as the NAD+ goes in. It is a vasodilation effect, it tracks with infusion speed, and it fades as the rate slows or the infusion ends. Worth noting for the precursor-curious: this is not the niacin "flush" (that is a separate, receptor-mediated reaction to high-dose niacin) — oral NR and NMN precursors generally do not cause it. Community practice is simply to slow the drip and let the warmth pass; it rarely needs more than that.

Nausea (24%, 168 users) and abdominal cramping (12%, 84 users)

The GI side of the rush. Nausea is tagged moderate because it is the effect most likely to make someone want to stop, and cramping often rides along with it. Both are classic fast-infusion sensations: push NAD+ quickly and the gut protests; slow the drip and they typically settle. The community approach is conservative: slow the rate at the first wave, sip water, eat something light beforehand, and resume slower. Nausea that does not ease on slowing, or comes with vomiting you cannot control, is a reason to pause and reassess.

Chest tightness or pressure (22%, 154 users)

Covered in the decision block above, but in the per-effect list it belongs here as the third most-reported effect and a "moderate" tag. The short version: it is the most alarming part of the rush and one of the most clearly rate-dependent, easing on a slower drip. For most people it is benign and rate-related; for anyone with cardiac history it is the effect to take seriously rather than ride out. When in doubt, slow or stop and get checked.

Increased heart rate (10%, 70 users) and the systemic tail (sweating, anxiety, fatigue, 8% each)

A faster pulse, sweating, and a jittery or restless feeling round out the rush; they are the body's response to a rapid systemic load and, like the rest, track with rate. Anxiety and restlessness in our notes specifically cluster "during fast infusions." Fatigue tends to show up afterward, and is usually mild. None of these were tagged severe. The handling is the same theme: slow down, breathe, and let the rate do the work.

Infusion or injection-site reaction (16%, 112 users) and headache (14%, 98 users)

The two effects that are not purely about rate. An infusion or injection-site reaction (redness, stinging, or a small bump) is the expected local effect of any IV line or subcutaneous injection, handled with standard injection hygiene and site rotation. Headache and lightheadedness (12%) are mild and non-specific, often tied to the same vasodilation and to hydration; they usually settle with a slower rate and fluids. As always, persistent or worsening symptoms are a reason to stop and check in with a clinician.

When do effects start and ease? (the time-course)

The time-course is the tell that this is a rate phenomenon. Unlike a drug whose side effects build over days, the NAD rush is infusion-locked: it appears during the push, scales with how fast the drip runs, and in the published real-world data ceased immediately when the infusion finished. That is why "slow the drip" works so reliably and why the standard clinic move is a long, slow infusion (commonly 2 to 4 hours) rather than a fast one. The flip side is honest: because there is no long-term human safety study of repeated IV NAD+, a clean infusion tells you the rush was managed, not that chronic use is validated as safe.

Our take: The most useful NAD+ tolerability habit is boring and it works: go slow. Almost every effect on this page is a rate effect, so the lever that fixes the rush is the roller clamp, not toughing it out. Tell the clinician the moment the warmth or tightness starts, slow or pause the drip, and resume at a gentler rate. Comfort beats speed, and with NAD+ that is not a metaphor.

Does the route matter? IV vs SubQ vs IM NAD+ side effects

Route matters more than most pages admit, and it mostly changes whether you get the infusion rush or a local reaction: a fast IV push produces the classic rush, a slow IV drip blunts it, subcutaneous (SubQ) injection trades the rush for more injection-site reactions and a slower onset, and intramuscular (IM) is uncommon and falls in between. The honest caveat: none of these route profiles has validated human incidence, so the comparison below is a synthesis of community report and clinic practice, not trial data.

The logic follows directly from the rate mechanism. Because the rush is driven by how fast NAD+ hits the bloodstream, an IV bolus or fast drip is the route most likely to produce flushing, nausea, and chest tightness, and a slow IV drip tames them. Subcutaneous dosing releases NAD+ gradually, so it swaps the systemic rush for more local reactions (stinging, redness, a bump) and a slower onset. Intramuscular NAD+ is the least-discussed route, used less often, sitting between the two. The table summarizes the practical pattern.

How honest can we be about NAD+ side-effect data?

Very honest, and it cuts two ways: the reassuring news is that the published evidence supports the rate story — slow infusions are well tolerated, and oral precursors barely cause side effects — but the limiting news is that there is no validated incidence table for IV or injected NAD+, so every percentage on this page is a self-reported signal, not a clinical rate. For an approved drug we would put our community numbers next to a controlled adverse-event table. For IV NAD+, that table does not exist.

What the published literature does support is the central claim of this page. A 2019 pilot that infused NAD+ slowly (about 2 mg/min over 6 hours) reported no adverse events, and a 2026 real-world pilot found that the symptoms IV NAD+ recipients did get appeared during the infusion and stopped the moment it ended, the fingerprint of a rate effect rather than toxicity. That pilot was tiny (14 people total), so it is honest data, not definitive data. The strongest tolerability evidence is actually for the oral precursors, which sidestep the rush entirely: randomized trials of nicotinamide riboside (NR) at up to 1,000 to 3,000 mg/day and nicotinamide mononucleotide (NMN) at up to 900 to 1,250 mg/day reported side effects comparable to placebo, with no flushing. Precursors do not cause a rush because they are absorbed gradually, the same reason a slow IV drip is gentler than a fast one.

The honesty band, then, is "community report versus a thin but consistent literature that all points the same way." Our 30% flushing and 22% chest-tightness figures are report signals about how often people feel the rush, not validated incidence; their value is the pattern (rate-driven, ease-on-slowing) that the published pilots independently confirm. One reject note: some clinic pages circulate dramatic figures (one cites a "44.5% anaphylactoid reaction" rate) that are unsourced and implausible, and we do not repeat them. Absence of validated harm is not proof of safety.

Citation capsule. No validated human incidence exists for IV or injected NAD+ side effects. The supporting literature is consistent but small: slow IV NAD+ (~2 mg/min over 6 hours) produced no adverse events (Grant 2019, n=11); a real-world pilot found IV NAD+ symptoms appeared during the infusion and ceased on completion (Reyna 2026, n=14 total); and oral precursors NR (up to 1,000-3,000 mg/day) and NMN (up to 900-1,250 mg/day) reported adverse events comparable to placebo with no flushing (Martens 2018; Conze 2019; Brakedal 2023; NMN multicenter RCT 2022). Source: peer-reviewed NAD+/NMN/NR literature, 2018-2026.

Why does NAD+ cause the rush — and why is it not a peptide?

The "NAD rush" happens because a rapid load of NAD+ drives transient vasodilation and smooth-muscle effects faster than the body can buffer, so you feel warmth, pressure, nausea, and a racing pulse — slow the delivery and the body keeps up, so the rush never builds. That single rate-versus-buffering idea explains the whole top of the chart, and it is why the fix is delivery speed, not a different molecule.

A couple of mechanism points clear up common confusion. First, infused NAD+ is largely broken down outside the cell into precursors (NMN and NR) before uptake, so a fast IV floods that extracellular processing pathway, part of why speed matters. Second, the niacin flush is a different thing: that is a receptor-mediated reaction to high-dose niacin, whereas the NAD-infusion flush is a vasodilatory, rate-driven phenomenon, which is why NR and NMN precursors do not produce it. And finally, the naming point that brings many readers here: NAD+ is a coenzyme, a dinucleotide your cells use in energy metabolism — it is not a peptide. Peptides are short chains of amino acids; NAD+ has no amino-acid chain. It gets filed under "peptides" on clinic menus, but it is a different category of molecule, which is why its side-effect story looks nothing like a typical injectable peptide's. For the full science and the IV-versus-oral comparison, see the NAD+ complete guide.

Who should be especially cautious with NAD+?

Because IV and injected NAD+ have no validated human safety data, the cautious default is "not without a clinician" — and the caution is sharper for anyone with a cardiac history or high blood pressure (given the chest-tightness and heart-rate effects), anyone pregnant or trying to conceive, and anyone tempted by an unregulated at-home product. These are not contraindications from a label, because no label exists; they follow from the mechanism and the missing data.

A few practical lines follow from everything above. If you have heart disease, an arrhythmia, or high blood pressure, the rate-driven cardiovascular sensations (chest tightness, faster pulse) are the reason to clear NAD+ with your clinician first and to default to stopping rather than riding out chest symptoms. Pregnancy and fertility are simply unstudied for IV NAD+, which makes "avoid" the conservative call. And because clinic-grade and research-grade NAD+ is unregulated for at-home use, product quality (sterility, mislabeled concentration, contamination) is its own risk on top of the molecule, and a too-fast self-administered push is exactly how people turn a manageable rush into a frightening one; for how to think about sourcing, see how to vet peptide quality. None of this page replaces a clinician conversation; with an unapproved, un-validated therapy that conversation matters more, not less.

Frequently Asked Questions

The bottom line

If you came here worried about NAD+ side effects, the most useful thing to know is that they are usually a speed problem, not a toxicity problem. The effects our 700 users report most often — flushing (30%), nausea (24%), chest tightness (22%), cramping — are the classic "NAD rush," clustering at the top of the list precisely because they are driven by how fast the NAD+ goes in. Slow the drip and most of that wave never builds, which is why clinics run NAD+ over hours rather than minutes. No one in our community-reported set logged a severe event.

The honest caveats sit right next to that reassurance. The chest-tightness sensation is alarming even when it is benign, so the rule is clear: it is usually the rush and eases on slowing, but if you have any cardiac history, treat chest symptoms seriously and stop to get checked. IV and injected NAD+ have no validated human incidence, so our figures are a self-reported signal, not proof of safety — backed by a small but consistent literature, not a large one. And NAD+ is a coenzyme, not a peptide, which is why its side-effect story is its own. From here, the natural next reads are the NAD+ complete guide for the molecule and the IV-versus-oral science, the NAD+ dosage calculator for how protocols and rates are structured, and how to vet peptide quality if you are sourcing product.

Sources

• Grant R, Berg J, Mestayer R, et al. "A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+." Frontiers in Aging Neuroscience, 2019;11:257. Slow infusion (~2 mg/min over 6 h) with no adverse events. Retrieved 2026-06-18. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2019.00257/full
• Reyna K, et al. "Intravenous infusion of NAD+ versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting." Frontiers in Aging, 2026;7:1652582. Infusion-time symptoms (cramping, nausea, increased heart rate, throat pain, chest pressure) ceasing immediately on completion. Retrieved 2026-06-18. https://pmc.ncbi.nlm.nih.gov/articles/PMC12907335/
• Alegre GFS, Pastore GM. "NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health." Current Nutrition Reports, 2023. Extracellular NAD+/NMN processing and route/PK differences. Retrieved 2026-06-18. https://pmc.ncbi.nlm.nih.gov/articles/PMC10240123/
• Martens CR, Denman BA, Mazzo MR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications, 2018;9:1286. NR well tolerated, no flushing. Retrieved 2026-06-18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876407/
• Conze D, Brenner C, Kruger CL. "Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Healthy Overweight Adults." Scientific Reports, 2019;9:9772. NR 100/300/1000 mg/day well tolerated. Retrieved 2026-06-18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611812/
• Brakedal B, et al. "A randomized, double-blind safety trial of high-dose nicotinamide riboside (NR-SAFE) in Parkinson's disease." Nature Communications, 2023. NR 3000 mg/day for 30 days, adverse events comparable to placebo. Retrieved 2026-06-18. https://www.nature.com/articles/s41467-023-43514-6
• "A multicentre, randomised, double-blind, placebo-controlled study on the efficacy and safety of NMN supplementation." NMN multicenter RCT (PMC9735188), 2022. NMN 300/600/900 mg/day for 60 days well tolerated; adverse events comparable to placebo. Retrieved 2026-06-18. https://pmc.ncbi.nlm.nih.gov/articles/PMC9735188/
• Cleveland Clinic Health Essentials. "NAD+ Supplements: Can They Really Slow Down Aging?" 2024. General NAD+ safety framing (oral). Retrieved 2026-06-18. https://health.clevelandclinic.org/nad-supplement
• ProtocolPlus. "Community-reported tolerability data: NAD+" (side-effects/nad-plus.json). First-party app data, 2026. N = 700 users who tracked NAD+ tolerability. Self-reported community frequency, not validated incidence and not proof of causation.